Kinase Inhibitor Discovery
with an untiring quest for future therapeutics

FY2024 Q3 Presentation

Consolidated Financial Results for the Third Quarter of the Year Ending December 31, 2024

Carna announces acceptance of two posters on docirbrutinib (AS-1763) for presentation at ASH Annual Meeting

Carna Announces International Nonproprietary Name Selection for AS-1763

Carna Initiates Dosing in Dose Expansion Part of Phase 1b Study of AS-1763, a Next Generation, Pan-Mutant Inhibitor of BTK

Carna Opens Dose Expansion Part of Phase 1b Study for Next Generation BTK Inhibitor AS-1763

FY2024 Q2 Presentation

Consolidated Financial Results for the Second Quarter of the Year Ending December 31, 2024